JAK1 and rheumatoid arthritis: Tofacitinib citrate is approved for medical use “to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to or are intolerant of methotrexate”.395–399 Baricitinib, sold under Oluminant, acts as a JAK1 and JAK2 inhibitor.